Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Reprod Fertil ; 4(2)2023 Apr 13.
Artículo en Inglés | MEDLINE | ID: mdl-39225137

RESUMEN

Females are born with a finite number of oocytes, collectively termed the ovarian reserve, established within the developing fetal ovary. Consequently, maternal exposure to reproductive toxicants can have harmful effects on the future fertility of her unborn female fetus. The chemical benzo[a]pyrene (B[a]P) is a prominent component of cigarette smoke. Despite it being a known ovotoxicant, around 8% of women in Europe smoke during pregnancy. The purpose of this research was to examine the effect of B[a]P on the developing ovary, using the mouse as a model and with experiments carried out in vitro. B[a]P-exposure to the fetal ovary prior to follicle formation reduced the number of germ cells and subsequently, the number of healthy primordial follicles, by up to 76%; however, while proliferation of germ cells was not affected, the germ cells contained higher levels of DNA double-strand breaks. Exposure to B[a]P also affected the proportion of oocytes progressing through prophase I of meiosis. B[a]P exposure to neonatal mouse ovaries, after follicle formation, resulted in an 85% reduction in the number of healthy follicles, with a corresponding increase in apoptotic cell death and reduction in somatic cell proliferation. Although there was a trend towards a higher level of oxidative stress in B[a]P-exposed ovaries, this was not statistically significant; likewise, the antioxidant melatonin failed to protect against the B[a]P-induced ovarian damage. Together, the results here demonstrate that B[a]P-exposure damages the developing ovary, both before and shortly after follicle formation, an effect that could lead to a subsequent decrease in fertility.


Asunto(s)
Apoptosis , Benzo(a)pireno , Ovario , Estrés Oxidativo , Animales , Benzo(a)pireno/toxicidad , Femenino , Ovario/efectos de los fármacos , Ovario/patología , Ovario/crecimiento & desarrollo , Ratones , Estrés Oxidativo/efectos de los fármacos , Apoptosis/efectos de los fármacos , Oocitos/efectos de los fármacos , Oocitos/crecimiento & desarrollo , Oocitos/metabolismo , Folículo Ovárico/efectos de los fármacos , Folículo Ovárico/crecimiento & desarrollo , Folículo Ovárico/patología , Folículo Ovárico/metabolismo , Proliferación Celular/efectos de los fármacos , Animales Recién Nacidos , Embarazo , Daño del ADN/efectos de los fármacos
3.
BMC Cancer ; 16(1): 482, 2016 08 11.
Artículo en Inglés | MEDLINE | ID: mdl-27510889

RESUMEN

BACKGROUND: As with many anti-cancer drugs, the topoisomerase II inhibitor etoposide is considered safe for administration to women in the second and third trimesters of pregnancy, but assessment of effects on the developing fetus have been limited. The purpose of this research was to examine the effect of etoposide on germ cells in the developing ovary. Mouse ovary tissue culture was used as the experimental model, thus allowing us to examine effects of etoposide on all stages of germ cell development in the same way, in vitro. RESULTS: Fetal ovaries from embryonic day 13.5 CD1 mice or neonatal ovaries from postnatal day 0 CD1 mice were cultured with 50-150 ng ml(-1) or 50-200 ng ml(-1) etoposide respectively, concentrations that are low relative to that in patient serum. When fetal ovaries were treated prior to follicle formation, etoposide resulted in dose-dependent damage, with 150 ng ml(-1) inducing a near-complete absence of healthy follicles. In contrast, treatment of neonatal ovaries, after follicle formation, had no effect on follicle numbers and only a minor effect on follicle health, even at 200 ng ml(-1). The sensitivity of female germ cells to etoposide coincided with topoisomerase IIα expression: in the developing ovary of both mouse and human, topoisomerase IIα was expressed in germ cells only prior to follicle formation. CONCLUSIONS: Exposure of pre-follicular ovaries, in which topoisomerase IIα expression was germ cell-specific, resulted in a near-complete elimination of germ cells prior to follicle formation, with the remaining germ cells going on to form unhealthy follicles by the end of culture. In contrast, exposure to follicle-enclosed oocytes, which no longer expressed topoisomerase IIα in the germ cells, had no effect on total follicle numbers or health, the only effect seen specific to transitional follicles. Results indicate the potential for adverse effects on fetal ovarian development if etoposide is administered to pregnant women when germ cells are not yet enclosed within ovarian follicles, a process that starts at approximately 17 weeks gestation and is only complete towards the end of pregnancy.


Asunto(s)
Antineoplásicos Fitogénicos/toxicidad , Diferenciación Celular/efectos de los fármacos , Etopósido/toxicidad , Células Germinativas/patología , Oocitos/patología , Folículo Ovárico/patología , Ovario/patología , Animales , Células Cultivadas , Femenino , Células Germinativas/efectos de los fármacos , Ratones , Oocitos/efectos de los fármacos , Folículo Ovárico/efectos de los fármacos , Ovario/efectos de los fármacos
4.
Sci Rep ; 6: 22279, 2016 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-26931299

RESUMEN

The development of fetal ovarian follicles is a critical determinant of adult female reproductive competence. Prolonged exposure to environmental chemicals (ECs) can perturb this process with detrimental consequences for offspring. Here we report on the exposure of pregnant ewes to an environmental mixture of ECs derived from pastures fertilized with sewage sludge (biosolids): a common global agricultural practice. Exposure of pregnant ewes to ECs over 80 day periods during early, mid or late gestation reduced the proportion of healthy early stage fetal follicles comprising the ovarian reserve. Mid and late gestation EC exposures had the most marked effects, disturbing maternal and fetal liver chemical profiles, masculinising fetal anogenital distance and greatly increasing the number of altered fetal ovarian genes and proteins. In conclusion, differential temporal sensitivity of the fetus and its ovaries to EC mixtures has implications for adult ovarian function following adverse exposures during pregnancy.


Asunto(s)
Contaminantes Ambientales/toxicidad , Feto/efectos de los fármacos , Ovario/embriología , Animales , Femenino , Feto/anatomía & histología , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Laminina/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Exposición Materna , Proteínas Nucleares/metabolismo , Folículo Ovárico/efectos de los fármacos , Folículo Ovárico/embriología , Folículo Ovárico/metabolismo , Ovario/efectos de los fármacos , Ovario/metabolismo , Embarazo , Transporte de Proteínas/efectos de los fármacos , Proteoma/metabolismo , Aguas del Alcantarillado/química , Ovinos/embriología , Ovinos/genética , Factores de Tiempo , Transcriptoma/efectos de los fármacos , Transcriptoma/genética
5.
Reprod Toxicol ; 49: 117-35, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25150138

RESUMEN

There is increasing evidence to indicate that a substantial number of both man-made and naturally occurring chemicals are disruptive to human and wildlife reproductive health. Currently, reproductive toxicology testing is primarily carried out in vivo, however, in the past 50 years, various culture methods have been developed with the aim of growing ovarian follicles in vitro. These culture systems have become a widely used tool in reproductive biology and toxicology. In this review we describe how reproductive toxicology of the ovary is greatly enhanced by in vitro studies. Experiments using in vitro ovarian cultures to understand or detect damage to the ovary itself and to its specialised structures of the follicles and oocytes, allows for faster screening of potential developmental and/or reproductive toxicants.


Asunto(s)
Ovario/efectos de los fármacos , Técnicas de Cultivo de Tejidos/métodos , Pruebas de Toxicidad/métodos , Animales , Células Cultivadas/efectos de los fármacos , Femenino , Humanos , Oocitos/efectos de los fármacos , Folículo Ovárico/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA